BackgroundCheck.run
Search For

James Charles Geoghegan, 47Enfield, NH

Known as:
James C Geoghegan James C Geoghegian
Related to:
Vicky Gonis 57 Jennifer Stockton Kuijpers 62

James Geoghegan Phones & Addresses

Enfield, NH   

Lebanon, NH   

Canaan, NH   

Gaithersburg, MD   

144 Goose Pond Rd, Lyme, NH 03768   

Iowa City, IA   

Hanover, NH   

West Lebanon, NH   

Seattle, WA   

593 Grafton Turnpike Rd, Canaan, NH 03741   

Get Report
Control this profile

Mentions for James Charles Geoghegan

James Geoghegan resumes & CV records

Resumes

James Geoghegan Photo 28

Senior Scientist I

Location:
Lebanon, NH
Industry:
Biotechnology
Work:
Adimab, Llc
Senior Scientist I Adimab, Llc Jan 1, 2016 - Dec 2018
Scientist Ii Medimmune Jul 2013 - Dec 2015
Scientist I University of Iowa Jul 2009 - Jun 2013
Postdoctoral Research Fellow Adimab, Llc Jun 2008 - Jun 2009
Industrial Postdoc Celltech 1999 - 2003
Associate Scientist
Education:
Geisel School of Medicine at Dartmouth 2003 - 2008
Doctorates, Doctor of Philosophy, Biochemistry Oberlin College 1995 - 1999
Bachelors, Bachelor of Arts
Skills:
Antibody Discovery, Antibody Engineering, Antibody Developability, Protein Engineering, Assay Development, Epitope Mapping, Binding Kinetics, Antibodies, Protein Analytics, Protein Expression, Gene Therapy, Aav, Bioassay Development, Molecular Biology, Western Blotting, Cell Biology, Qpcr, Cell Culture, Sds Page, Biochemistry, Neurodegeneration, Molecular Cloning
James Geoghegan Photo 29

James Geoghegan

James Geoghegan Photo 30

James Geoghegan

Publications & IP owners

Wikipedia

James Geoghegan Photo 31

James Geoghegan

James Geoghegan (8 December 1886 27 March 1951) was an Irish politician, and later a justice of the Supreme Court. He was first elected to Dil ireann in a

Us Patents

Anti-Cd25 Antibody Agents

US Patent:
2021000, Jan 14, 2021
Filed:
Feb 5, 2020
Appl. No.:
16/782461
Inventors:
- Hertfordshire, GB
- London, GB
Josephine Salimu - Hertfordshire, GB
Kevin Moulder - Hertfordshire, GB
Pascal Merchiers - Hertfordshire, GB
Mark Brown - Hertfordshire, GB
Sergio Quezada - London, GB
James Geoghegan - Lyme NH, US
Bianka Prinz - Lebanon NH, US
International Classification:
C07K 16/28
A61P 35/02
C12N 15/85
A61P 35/00
A61K 39/395
C07K 14/55
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Anti-Cd25 For Tumour Specific Cell Depletion

US Patent:
2021000, Jan 14, 2021
Filed:
Mar 13, 2019
Appl. No.:
16/979929
Inventors:
- Hertfordshire, GB
- London, GB
Josephine Salimu - Hertfordshire, GB
Kevin Moulder - Hertfordshire, GB
Pascal Merchiers - Hertfordshire, GB
Mark Brown - Hertfordshire, GB
James Geoghegan - Lyme NH, US
Bianka Prinz - Lebanon NH, US
Sergio Quezada - London, GB
International Classification:
C07K 16/28
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Anti-Cd25 For Tumour Specific Cell Depletion

US Patent:
2021000, Jan 14, 2021
Filed:
Mar 13, 2019
Appl. No.:
16/979930
Inventors:
- Hertfordshire, GB
- London, GB
Josephine Salimu - Hertfordshire, GB
Kevin Moulder - Hertfordshire, GB
Pascal Merchiers - Hertfordshire, GB
Mark Brown - Hertfordshire, GB
James Geoghegan - Lyme NH, US
Bianka Prinz - Lebanon NH, US
Sergio Quezada - London, GB
International Classification:
C07K 16/28
A61K 39/395
A61K 45/06
A61P 35/00
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Anti-Cd25 For Tumour Specific Cell Depletion

US Patent:
2021000, Jan 14, 2021
Filed:
Mar 13, 2019
Appl. No.:
16/979935
Inventors:
- Hertfordshire, GB
- London, GB
Josephine Salimu - Hertfordshire, GB
Kevin Moulder - Hertfordshire, GB
Pascal Merchiers - Hertfordshire, GB
Mark Brown - Hertfordshire, GB
James Geoghegan - Lyme NH, US
Bianka Prinz - Lebanon NH, US
Sergio Quezada - London, GB
International Classification:
C07K 16/28
A61K 39/395
A61K 45/06
A61P 35/00
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Anti-Cd25 Antibody Agents

US Patent:
2020040, Dec 31, 2020
Filed:
Feb 5, 2020
Appl. No.:
16/782440
Inventors:
- Hertfordshire, GB
- London, GB
Josephine Salimu - Hertfordshire, GB
Kevin Moulder - Hertfordshire, GB
Pascal Merchiers - Hertfordshire, GB
Mark Brown - Hertfordshire, GB
Sergio Quezada - London, GB
James Geoghegan - Lyme NH, US
Bianka Prinz - Lebanon NH, US
International Classification:
C07K 16/28
A61P 35/02
C12N 15/85
A61P 35/00
A61K 39/395
C07K 14/55
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Binding Molecules Specific For Cd73 And Uses Thereof

US Patent:
2020007, Mar 12, 2020
Filed:
Nov 8, 2019
Appl. No.:
16/678165
Inventors:
- Cambridge, GB
Kris SACHSENMEIER - Gaithersburg MD, US
Erin SULT - Gaithersburg MD, US
Qihui Huang - Gaithersburg MD, US
Peter PAVLIK - Gaithersburg MD, US
Melissa DAMSCHRODER - Gaithersburg MD, US
Li CHENG - Gaithersburg MD, US
Gundo DIEDRICH - Gaithersburg MD, US
Jonathan RIOS-DORIA - Gaithersburg MD, US
Scott HAMMOND - Gaithersburg MD, US
Ralph MINTER - Cambridge, GB
Steve RUST - Cambridge, GB
Sandrine GUILLARD - Cambridge, GB
Robert HOLLINGSWORTH - Gaithersburg MD, US
Lutz JERMUTUS - Cambridge, GB
Nicholas DURHAM - Gaithersburg MD, US
Ching Ching LEOW - Gaithersburg MD, US
Mary ANTONYSAMY - Gaithersburg MD, US
James GEOGHEGAN - Gaithersburg MD, US
Xiaojun LU - Gaithersburg MD, US
Kim ROSENTHAL - Gaithersburg MD, US
International Classification:
C07K 16/40
A61K 47/68
C07K 16/28
Abstract:
The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Anti-Cd25 Antibody Agents

US Patent:
2019032, Oct 24, 2019
Filed:
Mar 13, 2019
Appl. No.:
16/352703
Inventors:
- Hertfordshire, GB
- London, GB
Josephine Salimu - Hertfordshire, GB
Kevin Moulder - Hertfordshire, GB
Pascal Merchiers - Hertfordshire, GB
Mark Brown - Hertfordshire, GB
Sergio Quezada - London, GB
James Geoghegan - Lyme NH, US
Blanka Prinz - Lebanon NH, US
International Classification:
C07K 16/28
A61K 39/395
A61P 35/00
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Anti-Cd25 Antibody Agents

US Patent:
2019030, Oct 3, 2019
Filed:
Mar 13, 2019
Appl. No.:
16/352709
Inventors:
- HERTFORDSHIRE, GB
- LONDON, GB
JOSEPHINE SALIMU - HERTFORDSHIRE, GB
KEVIN MOULDER - HERTFORDSHIRE, GB
PSCAL MERCHIERS - HERTFORDSHIRE, GB
MARK BROWN - HERTFORDSHIRE, GB
SERGIO QUEZADA - LONDON, GB
JAMES GEOGHEGAN - LYME NH, US
BIANKA PRINZ - LEBANON NH, US
International Classification:
C07K 16/28
A61K 39/395
A61P 35/00
Abstract:
The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Possible Relatives

David R Geoghegan  Daniel G Geoghegan  Denis M Geoghegan  Edward G Geoghegan  Elizabeth Geoghegan  George Geoghegan  Jacqueline A Geoghegan  James V Johnson  James C Stamps  James E Stanage 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.